Search Results - "Dubreuil P"

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer by Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.

“…Masitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent…”
Get full text

Systemic mastocytosis and bone involvement in a cohort of 75 patients by Barete, S, Assous, N, de Gennes, C, Grandpeix, C, Feger, F, Palmerini, F, Dubreuil, P, Arock, M, Roux, C, Launay, J M, Fraitag, S, Canioni, D, Billemont, B, Suarez, F, Lanternier, F, Lortholary, O, Hermine, O, Francès, C

“…To investigate bone involvement in a large cohort of systemic mastocytosis (SM) patients, and evaluate the efficacy of bisphosphonate therapy. From 2000 to…”
Get more information

Paediatric mastocytosis: a systematic review of 1747 cases by Méni, C., Bruneau, J., Georgin-Lavialle, S., Le Saché de Peufeilhoux, L., Damaj, G., Hadj-Rabia, S., Fraitag, S., Dubreuil, P., Hermine, O., Bodemer, C.

“…Summary Paediatric mastocytosis was previously considered to be a benign and spontaneously regressing disease. However, this evolution is impossible to…”
Get full text

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis by Arock, M, Sotlar, K, Akin, C, Broesby-Olsen, S, Hoermann, G, Escribano, L, Kristensen, T K, Kluin-Nelemans, H C, Hermine, O, Dubreuil, P, Sperr, W R, Hartmann, K, Gotlib, J, Cross, N C P, Haferlach, T, Garcia-Montero, A, Orfao, A, Schwaab, J, Triggiani, M, Horny, H-P, Metcalfe, D D, Reiter, A, Valent, P

“…Although acquired mutations in KIT are commonly detected in various categories of mastocytosis, the methodologies applied to detect and quantify the mutant…”
Get full text

The necessity of level IIb dissection for clinically negative neck oral squamous cell carcinoma by Garreau, B., Dubreuil, P.-A., Bondaz, M., Majoufre, C., Etchebarne, M.

“…Selective neck dissection reduces the incidence of complications associated with radical neck dissection while achieving the same oncological results,…”
Get full text

A high prevalence of hereditary alpha‐tryptasemia in pediatric mastocytoma by Madrange, M., Rossignol, J., Devin, C., Bekel, L., Bellon, N., Welfringer‐Morin, A., Méni, C., Bonigen, J., Bataille, P., Burdet, C., Agopian, J., Dubreuil, P., Hermine, O., Bodemer, C., Polivka, L.

Get full text

Masitinib is safe and effective for the treatment of canine mast cell tumors by Hahn, K.A, Oglivie, G, Rusk, T, Devauchelle, P, Leblanc, A, Legendre, A, Powers, B, Leventhal, P.S, Kinet, J.P, Palmerini, F, Dubreuil, P, Moussy, A, Hermine, O

“…Background: Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT). Hypothesis/Objective: To…”
Get full text

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial by Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B.A., Bulusu, V.R., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.

“…Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib…”
Get full text

DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice by Scourzic, L, Couronné, L, Pedersen, M T, Della Valle, V, Diop, M, Mylonas, E, Calvo, J, Mouly, E, Lopez, C K, Martin, N, Fontenay, M, Bender, A, Guibert, S, Dubreuil, P, Dessen, P, Droin, N, Pflumio, F, Weber, M, Gaulard, P, Helin, K, Mercher, T, Bernard, O A

“…TEN-ELEVEN-TRANSLOCATION-2 (TET2) and DNA-METHYLTRANSFERASE-3A (DNMT3A), both encoding proteins involved in regulating DNA methylation, are mutated in…”
Get full text

General and specific combining abilities in a maize (Zea mays L.) test-cross hybrid panel: relative importance of population structure and genetic divergence between parents by Larièpe, A., Moreau, L., Laborde, J., Bauland, C., Mezmouk, S., Décousset, L., Mary-Huard, T., Fiévet, J. B., Gallais, A., Dubreuil, P., Charcosset, A.

“…Key message General and specific combining abilities of maize hybrids between 288 inbred lines and three tester lines were highly related to population…”
Get full text

Paediatric mastocytosis: long‐term follow‐up of 53 patients with whole sequencing of KIT. A prospective study by Meni, C., Georgin‐Lavialle, S., Le Saché de Peufeilhoux, L., Jais, J.P., Hadj‐Rabia, S., Bruneau, J., Fraitag, S., Hanssens, K., Dubreuil, P., Hermine, O., Bodemer, C.

“…Summary Background Mastocytosis is a heterogeneous group of clinical disorders characterized by the abnormal accumulation of mast cells. The adult and…”
Get full text

The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis by Polivka, L., Parietti, V., Bruneau, J., Soucie, E., Madrange, M., Bayard, E., Rignault, R., Canioni, D., Fraitag, S., Lhermitte, L., Feroul, M., Tissandier, M., Rossignol, J., Frenzel, L., Cagnard, N., Meni, C., Bouktit, H., Collange, A.-F., Gougoula, C., Parisot, M., Bader-Meunier, B., Livideanu, C., Laurent, C., Arock, M., Hadj-Rabia, S., Rüther, U., Dubreuil, P., Bodemer, C., Hermine, O., Maouche-Chrétien, L.

“…Mastocytosis is a heterogeneous disease characterized by an abnormal accumulation of mast cells (MCs) in 1 or several organs. Although a somatic KIT D816V…”
Get full text

The genetic basis of heterosis: multiparental quantitative trait loci mapping reveals contrasted levels of apparent overdominance among traits of agronomical interest in maize (Zea mays L.) by Larièpe, A, Mangin, B, Jasson, S, Combes, V, Dumas, F, Jamin, P, Lariagon, C, Jolivot, D, Madur, D, Fiévet, J, Gallais, A, Dubreuil, P, Charcosset, A, Moreau, L

“…Understanding the genetic bases underlying heterosis is a major issue in maize (Zea mays L.). We extended the North Carolina design III (NCIII) by using three…”
Get full text

Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome by Degboé, Y., Eischen, M., Apoil, PA, Mailhol, C., Dubreuil, P., Hermine, O., Paul, C., Bulai Livideanu, C., Laroche, M.

“…Summary Little is known about osteoporosis in mast cell disorders (MCDs) not related to systemic mastocytosis. We described osteoporosis and fractures in MCDs…”
Get full text

Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL–1: why we should investigate further by Jendoubi, F., Shourick, J., Negretto, M., Laurent, C., Apoil, P.A., Evrard, S., Mansat‐De Mas, V., Severino‐Freire, M., Mailhol, C., Degboé, Y., Dubreuil, P., Hermine, O., Paul, C., Bulai Livideanu, C.

“…Dear Editor, Mastocytosis is a rare disease characterized by the accumulation/proliferation of abnormal mast cells (MCs).1 Mastocytosis is categorized into…”
Get full text

Loss of AF6 afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth by Fournier, G, Cabaud, O, Josselin, E, Chaix, A, Adélaïde, J, Isnardon, D, Restouin, A, Castellano, R, Dubreuil, P, Chaffanet, M, Birnbaum, D, Lopez, M

“…Afadin/AF6, an F-actin-binding protein, is ubiquitously expressed in epithelia and has a key role during development, through its regulatory role in cell–cell…”
Get full text

KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570 by Chaix, A, Arcangeli, M-L, Lopez, S, Voisset, E, Yang, Y, Vita, M, Letard, S, Audebert, S, Finetti, P, Birnbaum, D, Bertucci, F, Aurrand-Lions, M, Dubreuil, P, De Sepulveda, P

“…Mutation of KIT receptor tyrosine kinase at residue D816 results in ligand-independent constitutive kinase activity. This mutation occurs in most patients with…”
Get full text

An extensive spectroscopic time series of three Wolf–Rayet stars – II. A search for wind asymmetries in the dust-forming WC7 binary WR137 by St-Louis, N, Piaulet, C, Richardson, N D, Shenar, T, Moffat, A F J, Eversberg, T, Hill, G M, Gauza, B, Knapen, J H, Kubát, J, Kubátová, B, Sablowski, D P, Simón-Díaz, S, Bolduan, F, Dias, F M, Dubreuil, P, Fuchs, D, Garrel, T, Grutzeck, G, Hunger, T, Küsters, D, Langenbrink, M, Leadbeater, R, Li, D, Lopez, A, Mauclaire, B, Moldenhawer, T, Potter, M, dos Santos, E M, Schanne, L, Schmidt, J, Sieske, H, Strachan, J, Stinner, E, Stinner, P, Stober, B, Strandbaek, K, Syder, T, Verilhac, D, Waldschläger, U, Weiss, D, Wendt, A

“…ABSTRACT We present the results of a 4-month, spectroscopic campaign of the Wolf–Rayet dust-making binary, WR137. We detect only small-amplitude random…”
Get full text

Response to letter from Dr Jain by Zandecki, M., Dubreuil, P.

Get full text

Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis by Bulai Livideanu, C., Apoil, P. A., Lepage, B., Eischen, M., Laurent, C., Laharrague, P., Lamant, L., Tournier, E., Tavitian, S., Pouplard, C., Recher, C., Laroche, M., Mailhol, C., Dubreuil, P., Hermine, O., Blancher, A., Paul, C.

“…Summary Background Mastocytosis is difficult to diagnose, especially when systemic mast cell activation symptoms are not present or involve only one…”
Get full text